Guest Open Access Plus | Free Content | About | Sign in | New Users: Sign up | Mark List  

Current Topics in Medicinal Chemistry

Volume 12 Issue 5
ISSN: 1568-0266
eISSN: 1873-5294


   All Titles

  Back to the Future: Lessons Learned in Modern Target-based and Whole-Cell Lead Optimization of Antimalarials
  pp.473-483 (11) Authors: Arnab K. Chatterjee, Bryan K.S. Yeung

Antimalarial drug discovery has historically benefited from the whole-cell (phenotypic) screening approach to identify lead molecules in the search for new drugs. However over the past two decades there has been a shift in the pharmaceutical industry to move away from whole-cell screening to target-based approaches. As part of a Wellcome Trust and Medicines for Malaria Venture (MMV) funded consortium to discover new blood-stage antimalarials, we used both approaches to identify new antimalarial chemotypes, two of which have progressed beyond the lead optimization phase and display excellent in vivo efficacy in mice. These two advanced series were identified through a cell-based optimization devoid of target information and in this review we summarize the advantages of this approach versus a target-based optimization. Although the each lead optimization required slightly different medicinal chemistry strategies, we observed some common issues across the different the scaffolds which could be applied to other cell based lead optimization programs.

  Keywords: Lead-optimization, malaria, whole-cell screening, spiroindolones, imidazolopiperazines, lead optimization phase, in vivo efficacy, scaffolds, dihydrofolate reductase inhibition (DHFR), HTS (high-throughput screen)
  Affiliation: Novartis Institute for Tropical Diseases, 10 Biopolis Road, &# 05-01 Chromos, Singapore 138670.
  Key: New Content Free Content Open Access Plus Subscribed Content

Bentham Science Publishers


  Copyright © 1994 - 2015   Bentham Science Publishers